No Data
Beijing Kanglecheng-B (01228.HK): Richard James Gregory appointed as a member of the audit committee.
On September 2, Geelong announced that due to Chen Kan's plan to spend more time on personal affairs, he has resigned as a non-executive director and a member of the audit committee, effective from September 2, 2024. After Chen Kan's resignation, independent non-executive director Richard James Gregory has been appointed as a member of the audit committee, effective from the effective date.
Performance: The half-year loss of Beihai Kangcheng (01228.HK) expanded to 0.247 billion RMB and no dividend will be distributed.
Beihai Kangcheng - B (01228.HK) announced its interim performance as of the end of June this year, with revenue of 44.794 million RMB, up 4% year-on-year. The loss expanded to 0.247 billion RMB, compared to a loss of 0.218 billion RMB in the same period last year; the loss per share was 58 cents. No dividend will be paid.
Beihai Kangcheng-B (01228.HK) has achieved significant growth in its mid-term performance, with a significant increase in research and development investment.
On August 30th, Gelonghui announced its interim performance. For the six months ended June 30, 2024, the group's revenue increased by CNY 1.7 million to CNY 44.8 million from CNY 43.1 million for the six months ended June 30, 2023. This is mainly due to the company's original plan to strategically focus on rare diseases in 2021, and the transition arrangement of Heidi An's distribution in Hong Kong will end in the second half of 2023. In addition to the sales in Hong Kong by Heidi An, the group's revenue increased by CNY 8.8 million or 24.4% compared to the same period in 2023, mainly due to Maier.
CANBRIDGE-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
Expectations of Fed rate cuts boost the Hong Kong stock market, with real estate and golden industrial concept stocks performing well.
①With the expectation of a rate cut by the Federal Reserve, which sectors are expected to benefit? ②Why did xpeng's stock surge today?
CANbridge Reports Positive Topline Data from CAN103 Pivotal Trial for Gaucher Disease in China, Plans NDA Filing in Q4 2024
No Data
No Data